Trial Profile
A Single and Multiple Ascending Dose, Placebo-Controlled, Double-Blind, Phase 1 Study of KY1005 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Amlitelimab (Primary)
- Indications Autoimmune disorders; Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Kymab
- 29 Jan 2022 Results published in the Clinical Pharmacology and Therapeutics
- 30 Jul 2018 According to a Kymab media release, the first subject first visit took place in June 2017 with last subject visit in March 2018.
- 30 Jul 2018 According to a Kymab media release, company has announced positive results of this study.